Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

Fri, 11th Mar 2022 11:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

DeepVerge PLC, up 6.9% at 15.50 pence, 12-month range 12.50p-36.25p. Production orders for its Modern Water division in the first quarter grew to GBP5 million and stated that it is transitioning its business model. Deepverge says orders received this quarter reflect year-on-year growth of 39% compared to orders worth GBP3.6 million a year before. These new orders for the Modern Water division also represent the biggest first-quarter production order in the history of the division. The equipment is expected to be delivered this year. The company stated that it will still deliver units as it transitions to monitoring. This includes units for a Chinese State government department and multiple units on its Yangtze River project, which are capital equipment sales.

----------

Mkango Resources Ltd, up 12% at 26.49 pence, 12-month range 19.00p-37.50p. Secures financing from European Raw Materials Alliance for the development of a rare earth separation plant in Poland. This plant will be supplied with rare earth carbonate from Mkango's Songwe Hill deposit of rare earth elements in Malawi. Mkango says the project will aid the creation of a secure supply chain option for neodymium, praseodymium, dysprosium, and terbium for the EU.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 9.5% at USD26.30, 12-month range USD26.30-USD77.60. Sinks to 12-month low as its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

----------

Omega Diagnostics Group PLC, down 11% at 3.68 pence, 12-month range 3.68p-98.50p. Says its Visitect Covid-19 antigen test has not been approved by the UK Health Security Agency for professional use. As a result, the product will not be available for sale in the UK. The company continues to work with external study centres to ensure the deadline for submission of self-test CE Mark data is met on March 31. Omega says it believes the self-test market to be "more relevant in terms of opportunity".

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2020 13:19

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Read more
3 Mar 2020 14:24

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Read more
25 Feb 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
12 Feb 2020 17:27

FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

By Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...

Read more
10 Feb 2020 07:36

Hutchison Chi-Med shares up on updated results from 'CALYPSO'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.

Read more
23 Jan 2020 15:06

Hutchison China Prices USD110 Million American Depositary Share Offer

Hutchison China Prices USD110 Million American Depositary Share Offer

Read more
22 Jan 2020 10:44

Hutchison China Plans USD110 Million American Depositary Share Offer

Hutchison China Plans USD110 Million American Depositary Share Offer

Read more
20 Jan 2020 16:00

Hutchison Chi-Med upbeat on progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.

Read more
20 Jan 2020 11:37

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Read more
13 Jan 2020 09:01

Hutchison China Starts Phase II Study For Cancer Treatment In China

Hutchison China Starts Phase II Study For Cancer Treatment In China

Read more
20 Dec 2019 15:48

Hutchison Chi-Med gets priority review for 'surufatinib' in China

(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.

Read more
20 Dec 2019 12:10

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Read more
28 Nov 2019 14:58

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Read more
25 Nov 2019 13:47

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Hutchison China MediTech Gets Orphan Designation For Surufatinib

Read more
12 Nov 2019 12:19

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.